About

On Target Therapeutics (oTTx) has a platform that accelerates development of candidate drugs.  The modifications introduced by oTTx enable expedited generation and characterization of peptide conjugates which are highly selective, long-lasting and efficacious.  The technology has been developed for G protein coupled receptors, the number one target class for drugs marketed in the Western world, yet can be adapted to modulate other cell surface proteins including channels and enzymes.  To date, we have developed candidate drugs showing efficacy in animal models of allergic asthma, neuropathic pain, short bowel and ocular inflammation/dry eyes. 

Ultimately, our goal is to develop a series of novel peptide therapeutics.  OTTx is currently performing preclinical investigations with the goal of extending into phase I or phase II trials.    OTTx is also actively seeking industry partners to participate in co-development efforts to bring these exciting new therapies to the clinic.